无症状重度主动脉瓣狭窄患者的跑步机负荷试验:EARLY TAVR随机临床试验的预设注册随访
该研究为EARLY TAVR试验的预设跑步机负荷试验(TST)注册随访,纳入美国75个中心的1250例筛查患者,其中962例符合标准,816例(84.8%)TST正常,146例(15.2%)TST阳性,105例阳性患者入组注册。TST安全,无死亡、晕厥或电复律;2年全因死亡率为5.7%,1年和2年主动脉瓣置换率分别为79.9%和85.9%。
要点
- 无症状重度AS患者中TST安全,可揭示症状并指导干预时机。
- TST阳性率约15%,阳性预测因素包括较高峰值流速、较低射血分数、既往CABG和卒中。
- TST阳性患者1年AVR率79.9%,但约20%在1年时仍未治疗。
核心结论
- 在无症状重度AS患者中,TST安全,约15%的患者通过TST发现症状和AVR指征。
- 然而,20%的TST阳性患者在1年时仍未接受治疗,尽管有及时治疗的指征。
研究设计与样本
- EARLY TAVR试验的预设TST注册研究,涉及美国75个临床中心。
- 2017年7月至2021年12月,1250例筛查患者中962例符合标准,816例(84.8%)TST正常,146例(15.2%)TST阳性,105例阳性患者入组注册并随访2年。
主要发现
- 105例分析患者平均(SD)年龄76.1(6.5)岁,80例(76.2%)为男性。
- TST安全,无死亡、晕厥或电复律报告。
- TST阳性的多变量基线预测因素包括较高峰值流速、较低射血分数、既往冠状动脉旁路移植和既往卒中。
- 2年全因死亡Kaplan-Meier率为5.7%;TST阳性患者1年和2年AVR率分别为79.9%和85.9%。
- 有AVR I类指征(测试中出现症状)和IIa类指征(收缩压下降)的患者死亡率和AVR率相似。
临床怎么用
- 对无症状重度AS患者,可考虑使用TST以揭示症状并评估AVR指征。
- TST阳性患者应积极考虑AVR,但需注意约20%在1年时仍未治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: In patients with asymptomatic severe aortic stenosis (AS), exercise stress testing is recommended to unmask symptoms and guide the timing of intervention, yet it is infrequently used in clinical practice. This registry-based follow-up of the Evaluation of TAVR Compared to Surveillance for Patients With Asymptomatic Severe Aortic Stenosis (EARLY TAVR) trial evaluates how treadmill stress testing (TST), used during screening for EARLY TAVR to confirm asymptomatic status, informed subsequent aortic valve replacement and clinical outcomes. OBJECTIVE: To evaluate clinical outcomes in patients with asymptomatic severe AS and a positive TST result and to identify predictors of a positive TST result. DESIGN, SETTING, AND PARTICIPANTS: This prespecified TST registry of the EARLY TAVR trial involved 75 clinical sites across the US. Between July 2017 and December 2021, apparently asymptomatic patients with severe AS underwent standardized TST. Those with normal TST results were randomized to transcatheter aortic valve replacement or clinical surveillance, whereas those with positive TST results were invited to enroll in a prospective registry and were followed up with through 2 years. Of 1250 patients screened, 962 met trial criteria. Of these, 816 (84.8%) had a normal TST result and 146 (15.2%) had a positive TST result. Of these, 105 consented to enroll in the EARLY TAVR Treadmill Registry. Data were analyzed from August 2025 to January 2026. EXPOSURE: Positive TST result. MAIN OUTCOMES AND MEASURES: TST-related safety, 2-year all-cause mortality, and rates of subsequent aortic valve replacement (AVR). Baseline predictors of a positive TST result were identified using multivariable logistic regression models. RESULTS: Of the 105 patients included in the present analysis, the mean (SD) age was 76.1 (6.5) years, and 80 participants (76.2%) were male. TST was found to be safe, with no reported deaths, syncope, or cardioversions. Multivariable baseline predictors of a positive TST included higher peak velocity, lower ejection fraction, prior coronary artery bypass, and prior stroke. The 2-year Kaplan-Meier rate for all-cause mortality was 5.7%. Among patients with positive TST results, the rates of AVR at 1 and 2 years were 79.9% and 85.9%, respectively. Rates of mortality and AVR were similar for patients who had a class I indication for AVR (symptoms during testing) and those with a class IIa indication (drop in systolic blood pressure). CONCLUSIONS AND RELEVANCE: In patients with asymptomatic severe AS, TST was found to be safe and identified symptoms and AVR indication in approximately 15% of patients. However, 20% of those patients remained untreated at 1 year, despite having an indication for prompt treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT03042104.
引用
- Généreux P, Schwartz A, Lindman BR, et al. Treadmill Stress Test in Patients With Asymptomatic Severe Aortic Stenosis: A Prespecified Registry-Based Follow-Up of the EARLY TAVR Randomized Clinical Trial. JAMA Cardiol. 2026. PMID: 42485012. doi:10.1001/jamacardio.2026.2527
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。